

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1579-321

C# M#

GARCIA-BLANCO et al

FEB 14 2001

Group Art Unit: 1642

Serial No. 09/465,802

Examiner: Hunt, J.

Filed: December 17, 1999

Date: February 12, 2001

Title: ALTERNATIVE SPLICING OF FIBROBLAST GROWTH FACTOR RECEPTOR 2  
MRNA IN PROSTATE CANCERAssistant Commissioner for Patents  
Washington, DC 20231

FEB 27 2001

Sir:

TECH CENTER 1600/2900  
RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes any attachments incorporated by reference and the signature below serves as the signature to the attachment. The signature thereon.

## Fees are attached as calculated below:

Total effective claims after amendment 0 minus highest number  
previously paid for 20 (at least 20) = 0 x \$ 18.00 0.00

Independent claims after amendment 0 minus highest number  
previously paid for 3 (at least 3) = 0 x \$ 80.00 0.00

If proper multiple dependent claims now added for first time, add \$270.00 (ignore improper) 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this  
paper and attachment(s) (\$110.00/1 month; \$390.00/2 months; \$890.00/3 months) 0.00

Terminal disclaimer enclosed, add \$ 110.00

- ☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$710.00)  
☐ Please enter the previously unentered, filed  
☐ Submission attached

- ☐ Request for Continued Examination pursuant to 37 C.F.R. § 1.114 (\$710.00) \$ 0.00  
☐ Please enter the previously unentered, filed  
or ☐ Required submission attached

Subtotal \$ 110.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 55.00  
☐ This application is entitled to "Small entity" status. ☐ "Small entity" statement attached.

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00

TOTAL FEE ENCLOSED \$ 55.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which  
should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No.  
14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
MJW:tat

NIXON & VANDERHYE P.C.  
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

GAU-1642

Box/Seq

WD

I hereby certify that this correspondence being  
deposited with the United States Postal Service as  
first class mail in an envelope addressed to:  
Commissioner of Patents and Trademarks,  
Washington, DC 20231 on  
2/12/01

Date of Deposit  
Mary J. Wilson, Reg. No. 32,955

Date of Signature

Signature


RECEIVED

MAR 01 2001

TECH CENTER 1600/2900

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-308-6900

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**